Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone.

Mikaelian I, Buness A, Hirkaler G, Fernandes R, Coluccio D, Geng W, Visalli T, Bachynsky MO, Berkofsky-Fessler W, Kanwal C, Hilton H, Nicklaus R, Hoflack JC, Dunn M, Sanders M, Giron M, Boyle BW, Singer T, Dick LS.

Toxicol Lett. 2011 Mar 5;201(2):110-5. doi: 10.1016/j.toxlet.2010.12.012. Epub 2010 Dec 21.

PMID:
21172411
2.

Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.

Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM.

Eur J Pharmacol. 2008 Oct 31;596(1-3):173-9. doi: 10.1016/j.ejphar.2008.08.004. Epub 2008 Aug 16.

PMID:
18761337
3.

Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.

Wang X, Liu X, Zhan Y, Lavallie ER, Diblasio-Smith L, Collins-Racie L, Mounts WM, Rutkowski JL, Xu X, Goltsman I, Abassi Z, Winaver J, Feuerstein GZ.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):820-9. doi: 10.1124/jpet.110.167635. Epub 2010 Jun 2.

4.

Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.

Rose M, Balakumar P, Singh M.

Pharmacology. 2007;80(2-3):177-84. Epub 2007 Jun 15.

PMID:
17570955
5.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036. Epub 2008 Feb 14.

PMID:
18346728
6.

Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.

Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, Shi L, Schroth G, Dragan YP.

Mol Divers. 2006 Aug;10(3):349-60. Epub 2006 Sep 21.

PMID:
17031537
7.

Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor alpha/gamma dual agonist using natriuretic peptides and imaging.

Engle SK, Solter PF, Credille KM, Bull CM, Adams S, Berna MJ, Schultze AE, Rothstein EC, Cockman MD, Pritt ML, Liu H, Lu Y, Chiang AY, Watson DE.

Toxicol Sci. 2010 Apr;114(2):183-92. doi: 10.1093/toxsci/kfp311. Epub 2009 Dec 31.

8.
9.

Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats.

Wu L, Wang R, De Champlain J, Wilson TW.

Am J Hypertens. 2004 Sep;17(9):749-56.

PMID:
15363815
11.

[An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis].

Zhao CY, Wang YD, Zhou JY, Jia B, Cui JF.

Zhonghua Gan Zang Bing Za Zhi. 2007 Jun;15(6):450-5. Chinese.

PMID:
17594812
12.

Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I.

Circulation. 2002 Mar 12;105(10):1240-6.

13.
14.

Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.

Sánchez-Hidalgo M, Martín AR, Villegas I, Alarcón De La Lastra C.

Biochem Pharmacol. 2005 Jun 15;69(12):1733-44.

PMID:
15876425
15.

Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.

Minoura H, Takeshita S, Kimura C, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Mutoh S.

Diabetes Obes Metab. 2007 May;9(3):369-78.

PMID:
17391165
16.

Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.

Hällsten K, Virtanen KA, Lönnqvist F, Janatuinen T, Turiceanu M, Rönnemaa T, Viikari J, Lehtimäki T, Knuuti J, Nuutila P.

Diabet Med. 2004 Dec;21(12):1280-7.

PMID:
15569129
17.

Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats.

Pelzer T, Jazbutyte V, Arias-Loza PA, Segerer S, Lichtenwald M, Law MP, Schäfers M, Ertl G, Neyses L.

Biochem Biophys Res Commun. 2005 Apr 8;329(2):726-32.

PMID:
15737646
18.

Assessment of the toxicity of hydralazine in the rat using an ultrasensitive flow-based cardiac troponin I immunoassay.

Mikaelian I, Coluccio D, Hirkaler GM, Downing JC, Rasmussen E, Todd J, Estis J, Lu QA, Nicklaus R.

Toxicol Pathol. 2009 Dec;37(7):878-81. doi: 10.1177/0192623309351894. Epub .

20.

PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.

Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.

Arch Pharm Res. 2009 May;32(5):721-7. doi: 10.1007/s12272-009-1511-8. Epub 2009 May 27.

PMID:
19471887
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk